The expanded service brings 10x Genomics-powered single-cell RNA sequencing to Novogene Europe's Cambridge Omics Centre, providing UK researchers with local access to end-to-end workflows and bioinformatics support.
From fleet-level monitoring to faster quantitative workflows, new expectations are emerging for how mass spectrometry platforms support decision-making at scale.
Sapient’s new mass spectrometry platform combines four workflows to map surface targets, signaling, immune activity and resistance mechanisms in tumor samples.
Harnessing multi-omics and AI, researchers are transforming drug discovery by revealing disease mechanisms, pinpointing therapeutic targets, and speeding up development.
Bristol Myers Squibb has initiated a phase 1 study of BMS-986506, a cereblon E3 ligase modulator jointly developed with Evotec, triggering a $10 million milestone.
Analytical performance begins long before a sample reaches the instrument, making sample preparation one of the most important determinants of data quality.